The synthetic lethality between BRCA1, BRCA2 and PARPi seen in pre-clinical models [38,39], also extends to clinical synthetic lethality [40], with PARPi now forming part of the standard-of-care approaches for the treatment of breast, ovarian, prostate or pancreatic cancers with defects in DNA repair by homologous recombination [41]. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.